News | November 21, 2011

VEITH Symposium Chairman Strongly Contests AHA Guidelines for Use of Carotid Artery Stenting in Symptomatic Patients

November 21, 2011 - Frank J. Veith, M.D., founder and chairman of the VEITH symposium, the William J. von Liebig Chair in Vascular Surgery, Cleveland Clinic and New York University Medical Center, took a strong position against the current guidelines of the American Heart Association (AHA) that support the use of carotid artery stenting (CAS), as opposed to the more traditional open carotid endarterectomy (CEA), to treat symptomatic carotid stenosis (CS) in low to moderate risk patients. Veith explained to an audience of his peers that an important clinical trial for CAS, the CREST (Carotid Revascularization Endarterectomy vs. Stent Trial), had results that appeared to show that the stent procedure (CAS) and the open surgical approach (CEA) were equivalent. Veith argued that the study was in fact flawed in several ways and that the AHA guideline was misguided.

The CREST study was designed to compare CEA and CAS in only symptomatic patients, but poor recruitment led to the inclusion of some asymptomatic patients. Adding these patients to the pool diluted the intended power of the original study, as asymptomatic patients with carotid stenosis have a different pathology and natural disease history. The study’s primary endpoint included death, stroke and myocardial infarction, and the difference in this combination endpoint for the CAS and CEA groups was in fact not significantly different. But Veith pointed out that when the individual endpoints (like total, major and minor strokes) were individually examined there were large differences in the incidence of these events in the two groups. However, since the additional asymptomatic patients had been added to the study population, these important findings were not significantly different and the AHA concluded from the results that the two procedures had similar results and therefore CAS could now be viewed as an alternative.

There were other challenges with the design and conduct of the study, including that the skills of the CAS physicians in this study were superior to and not representative of those doing the procedure in the “real world.” In addition, the CAS patients received more intensive antiplatelet treatment that the CEA patients, leading to possibly a lower MI rate after CAS.

Veith’s main assertion was that, because CAS causes more strokes than CEA, CAS is currently inferior to CEA, and CAS should not be considered an alternative or equivalent to CAE in most symptomatic patients and therefore the AHA guidelines are “misguided.”

For more information:

Related Content

Videos | Stents | September 11, 2018
This is an animation showing how the dedicated bifurcation stent developed by Advanced Bifurcation Systems (ABS) is d
Elixir Medical Corporation Unveils Transformational DynamX Stent Featuring Adaptive Segments that Uncage the Stented Artery
News | Stents | January 25, 2018
January 25, 2018 – Elixir Medical Corporation, a leader in the development of breakthrough adaptive remodeling techno
The TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

The presentation of the ESC late-breaker TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

News | Stents | November 24, 2017
November 24, 2017 – During a late-breaking session at the European Society of Cardiology (ESC) 2017 meeting, presente
News | Stents | November 10, 2017
Cordis, a Cardinal Health company, recently unveiled a comprehensive interventional cardiology portfolio, which now...
OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

Feature | Stents | November 08, 2017
November 8, 2017 – New results from the HARMONEE Japan/U.S.
FDA Approves COBRA REDUCE Trial of 14-Day DAPT With CeloNova Stent
News | Stents | October 27, 2017
CeloNova BioSciences Inc. announced the U.S. Food and Drug Administration (FDA) approved expansion of CeloNova's...
CeloNova Cobra Pzf stent
Technology | Stents | March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents | January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
EXCEL Trial, TCT 2016, drug-eluting stents, CABG, surgery left main heart disease, LMCAD

Gregg W. Stone, M.D., presenting the EXCEL data at TCT 2016 during a standing room only late-breaking trial session.

Feature | Stents | January 12, 2017 | Dave Fornell
The biggest news from the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting this past fall was the results
Biotronik's Osiro stent, prison IV trial

Biotronik's Osiro ultra-thin strut, sirolimus-eluting stent.

News | Stents | November 09, 2016
November 9, 2016 – Results from a randomized, multicenter trial failed to show non-inferiority of hybrid, ultra-thin
Overlay Init